NEU — Neuren Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$2.95bn
- AU$2.66bn
- AU$64.63m
Brief: Neuren Pharmaceuticals Says HY Net Loss Attributable A$7.1 Million
Brief: Neuren Pharmaceuticals Provides Half-Year Shareholder Update-
Brief: Neuren Pharmaceuticals Expects To Receive Revenue Over 2022 & 2023 For Rett Syndrome In U.S. Alone Of A$118 Mln
Commences Phase 2 Trial Of Nnz-2591 In Angelman Syndrome
Neuren begins Phase-2 trial for Angelman syndrome drug, shares rise
Brief: Neuren Pharmaceuticals Says Got U.S. FDA Approval For Pitt Hopkins Syndrome Ind And Phase 2 Trial
Australia Stock Exchange release from NEUREN PHARMACEU : PRE_NR Ends: 10:05:15
Australia Stock Exchange release from NEUREN PHARMACEU : FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
Australia's Neuren Pharma gains on FDA nod for phase-2 trial of PMS drug
Australia Stock Exchange release from NEUREN PHARMACEU : FDA approval for Phelan-McDermid IND and Phase 2 trial
Australia Stock Exchange release from NEUREN PHARMACEU : PRE_NR Ends: 09:55:20
Australia Stock Exchange release from NEUREN PHARMACEU : PRE_NR Ends: 09:44:28
Australia Stock Exchange release from NEUREN PHARMACEU : Ethics approval for Angelman Phase 2 trial in Australia
Australia Stock Exchange release from NEUREN PHARMACEU : PRE_NR Ends: 17:13:11
Australia Stock Exchange release from NEUREN PHARMACEU : S&P DJI Announces March 2022 Quarterly Rebalance
Australia Stock Exchange release from NEUREN PHARMACEU : Investor presentation 25 Feb 2022
Australia Stock Exchange release from NEUREN PHARMACEU : FDA approval for Angelman IND and Phase 2 trial
Australia Stock Exchange release from NEUREN PHARMACEU : PRE_NR Ends: 09:42:46
Brief: Neuren Pharmaceuticals Expects To Receive Revenue Over 2022 And 2023 For Rett Syndrome In Us Alone Of A$115 Million